Secondary Blood Grouping and Sickle Testing

The NHS Blood and Transplant organisation is engaging in a procurement process for a Managed Service Contract concerning secondary blood grouping and sickle cell testing. The process, currently in the planning stage as of October 2023, focuses on the procurement of automated blood group testing equipment. This initiative is set within the services category, particularly blood analysis, and is intended to be rolled out at locations in the UK, specifically Filton (Bristol) and Manchester donor testing sites.

A Public Information Notice suggests a potential Open procedure under the procurement method. Interested parties were encouraged to respond by November 2023 for further market engagement, with a resolution and market notice expected by February 2024. This procurement presents a promising opportunity for businesses specialising in medical testing equipment, particularly those offering comprehensive automated solutions for blood group testing and sickle cell screening.

Companies capable of providing an end-to-end integrated solution, including equipment, maintenance, consumables, and IT provisions with seamless compatibility with existing NHSBT systems, will likely find this tender aligns with their service offerings. Additionally, firms that can contribute to NHSBT's objectives of leveraging the latest technological advancements to enhance testing efficiency and accuracy will align well with the tender's requirements, potentially fostering significant business growth and diversification.